Antengene Corporation

Aug 12, 2020

Australian Therapeutic Goods Administration Approves the First Phase I Trial of ATG-017 for the Treatment of Patients with Advanced Solid Tumors and Hematological Malignancies

Jul 19, 2020

Antengene Corporation Closes US$97 Million Series C Financing to Support Ongoing Drug Development and Preparations for Potential Commercialization

Jul 01, 2020

Antengene Corporation Appoints Former BMS Senior Leader of Biostatistics Zhinuan YU as Corporate Vice President of Biometrics and Regulatory Enabling Functions

Jun 08, 2020

Antengene Corporation Appoints Mr. Donald Lung as Chief Financial Officer

May 05, 2020

Antengene Announces Expansion of Partnership with Karyopharm in Asia Pacific Markets

Apr 14, 2020

Antengene Announces Dosing of First Patient in the ATG-019 (KPT-9274) Phase 1 Trial, a First-in-Class Dual Inhibitor, for Advanced Solid Tumors and Non-Hodgkin's Lymphoma

Apr 13, 2020

Antengene Corporation Appoints Former Celgene ANZ General Manager Thomas Karalis as Head of Asia Pacific Regions